Procter & Gamble Company: Target Price Consensus and Analysts Recommendations | PG | US7427181091

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

165.86USD

Average target price

171.51USD

Spread / Average Target

+3.41%

High Price Target

186.00USD

Spread / Highest target

+12.14%

Low Price Target

140.00USD

Spread / Lowest Target

-15.59%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Piper Sandler
Redburn Atlantic
BNP Paribas Exane
BofA Securities
Deutsche Bank Securities
Truist Securities
Morgan Stanley
Wells Fargo Securities
Jefferies & Co.
TD Cowen
Goldman Sachs
Stifel Nicolaus
Evercore ISI
Raymond James
JPMorgan Chase
RBC Capital Markets
HSBC
RBC	Nik Modi
Barclays
Berenberg Bank
UBS
DA Davidson
President Capital Management
Citigroup
Wolfe Research
Argus
DZ Bank
Redburn
Consumer Edge
Bernstein
William Blair & Co.
Atlantic Equities
Credit Suisse
JPMORGAN	Andrea Teixeira
Independent Research
J.P. Morgan Chase

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2025-05-23 pm EDT			5-day change	1st Jan Change
165.86 ^USD	+0.50%		+1.58%	-1.07%

May. 08	Titan Mining Corporation Announces the Addition of 43,943 Acres of Mineral Rights Through Lease and Option Agreements with St. Lawrence County, New York	CI
May. 06	Procter & Gamble Insider Sold Shares Worth $1,669,200, According to a Recent SEC Filing	MT

Piper Sandler Adjusts Price Target on Procter & Gamble to $164 From $160, Maintains Neutral Rating	May. 05	MT
Redburn Atlantic Downgrades Procter & Gamble to Neutral From Buy, Adjusts PT to $161 From $176	May. 01	MT
BNP Paribas Exane Adjusts Procter & Gamble Price Target to $180 From $190, Maintains Outperform Rating	Apr. 25	MT
BofA Securities Cuts Price Target on Procter & Gamble to $180 From $190, Buy Rating Maintained	Apr. 25	MT
Analyst recommendations: Alphabet, Procter, Nasdaq, T-Mobile...	Apr. 25
PROCTER & GAMBLE CO : Upgraded to Buy by RBC	Apr. 25	ZD
Deutsche Bank Adjusts Procter & Gamble Price Target to $179 From $185, Maintains Buy Rating	Apr. 25	MT
Evercore ISI Adjusts Price Target on Procter & Gamble to $170 From $180, Maintains Outperform Rating	Apr. 25	MT
Stifel Adjusts Price Target on Procter & Gamble to $161 From $165, Maintains Neutral Rating	Apr. 25	MT
Goldman Sachs Adjusts Price Target on Procter & Gamble to $161 From $163, Maintains Neutral Rating	Apr. 25	MT
Truist Securities Adjusts Price Target on Procter & Gamble to $180 From $185, Maintains Buy Rating	Apr. 25	MT
TD Cowen Adjusts Price Target on Procter & Gamble to $175 From $189, Maintains Buy Rating	Apr. 25	MT
Jefferies Adjusts Price Target on Procter & Gamble to $159 From $167, Maintains Hold Rating	Apr. 25	MT
Wells Fargo Adjusts Price Target on Procter & Gamble to $175 From $185, Maintains Overweight Rating	Apr. 25	MT
Morgan Stanley Adjusts PT on Procter & Gamble to $180 From $191, Maintains Overweight Rating	Apr. 25	MT
Raymond James Adjusts PT on Procter & Gamble to $185 From $190, Maintains Outperform Rating	Apr. 25	MT
JPMorgan Adjusts PT on Procter & Gamble to $169 From $172, Maintains Overweight Rating	Apr. 25	MT
RBC Upgrades Procter & Gambleto Outperform From Sector Perform, Adjusts PT to $177 From $164	Apr. 25	MT
HSBC Cuts Price Target on Procter & Gamble to $185 From $187	Apr. 24	MT
Piper Sandler Adjusts Price Target on Procter & Gamble to $160 From $172, Maintains Neutral Rating	Apr. 24	MT
BNP Paribas Exane Adjusts PT on Procter & Gamble to $190 From $191, Maintains Outperform Rating	Apr. 22	MT
Barclays Adjusts Procter & Gamble's Price Target to $160 From $165, Keeps Equalweight Rating	Apr. 11	MT
JPMorgan Adjusts Price Target on Procter & Gamble to $172 From $181, Keeps Overweight Rating	Apr. 11	MT
Jefferies Adjusts Price Target on Procter & Gamble to $167 From $172, Keeps Hold Rating	Apr. 07	MT
Truist Securities Adjusts Price Target on Procter & Gamble to $185 From $180, Keeps Buy Rating	Apr. 03	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	PROCTER & GAMBLE COMPANY					+3.41%
	UNILEVER PLC					+2.66%
	COLGATE-PALMOLIVE COMPANY					+6.73%
	KENVUE INC.					+3.81%
	BEIERSDORF					+17.37%
	ESTEE LAUDER					+7.73%
	ESSITY AB					+10.53%
	GODREJ CONSUMER PRODUCTS LIMITED					+6.46%
	GIANT BIOGENE HOLDING CO., LTD.					+12.33%
	Average					+7.89%
	Weighted average by Cap.					+4.66%

Consensus Procter & Gamble Company

Equities

PG

US7427181091

Personal Products

Evolution of the Average Target: Procter & Gamble Company

Evolution of the Target Price: Procter & Gamble Company

Changes in Analyst Recommendations: Procter & Gamble Company

Analysts' recommendations: Procter & Gamble Company

Sector Comparison:

Analysts' Consensus

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Ratings

Quarterly revenue - Rate of surprise

Consensus Procter & Gamble Company

Equities

PG

US7427181091

Personal Products

Evolution of the Average Target: Procter & Gamble Company

Evolution of the Target Price: Procter & Gamble Company

Changes in Analyst Recommendations: Procter & Gamble Company

Analysts' recommendations: Procter & Gamble Company

Sector Comparison: Consumer Non-CyclicalsPersonal & Household Products & ServicesPersonal &Household Products & ServicesPersonal ProductsOther Personal Products

Analysts' Consensus

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Ratings

Quarterly revenue - Rate of surprise

Sector Comparison: